Description: ImpediMed Limited, together with its subsidiaries, develops, manufactures, and sells bioimpedance instruments, consumables, and software in Australia, North America, and internationally. The company operates through Medical and Test & Measurement segments. It offers SOZO, a next generation bioimpedance spectroscopy digital health platform; and L-Dex U400, a technology that utilizes the characteristics of frequency dependent current flow to quantify changes in extracellular fluid in the patient's limb. The company also provides SFB7, a tetra polar bioimpedance spectroscopy device that scans various frequencies for the estimation of body composition in healthy individuals; and ImpediVET, a bioimpedance spectroscopy technology for use in veterinary applications. In addition, the company supplies power precision testing and measuring equipment. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.
Home Page: www.impedimed.com
50 Parker Court
Pinkenba,
QLD
4008
Australia
Phone:
61 7 3860 3700
Officers
| Name | Title |
|---|---|
| Mr. Timothy Cruickshank | Chief Financial Officer |
| Mr. Shashi Tripathi | COO, CTO & Chief Customer Officer |
| Mr. Dennis Schlaht | Sr. VP of R&D and Technology |
| Ms. Catherine Kingsford | Sr. VP of Medical Affairs |
| Mr. David W. Anderson B.S. | Exec. Director |
| Mr. Richard P. Valencia | MD & CEO |
| Mr. Michael John Bassett | Chief Commercial Officer, Sr. VP of Corp. & Strategic Devel. and GM of Renal |
| Ms. Nancy T. Deisinger | Sr. VP of HR |
| Dr. Thomas Schenk | Chief Medical Officer |
| Ms. Leanne Ralph AAICD, ACIS, BBus | Company Sec. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7392 |
| Price-to-Sales TTM: | 9.2213 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 73 |